0001104659-26-038330
SEC filingXWELL faced persistent operating losses and cash burn in FY2025, driven by XpresTest revenue declines from reduced testing volumes, partially offset by Naples Wax growth, with closures stabilizing costs amid a post-year-end financing lifeline for liquidity.
XWELL, Inc. reported FY2025 results reflecting a challenging environment marked by revenue pressure from sharply reduced XpresTest volumes, though strategic actions provided some mitigation. Total revenue reached $29.2 million, with the decline driven primarily by lower testing activity in the XpresTest segment—a core business line sensitive to fluctuating demand for COVID-related and other diagnostic services. This topline contraction was partially offset by modest growth in service revenues from newly opened Naples Wax locations, demonstrating resilience in the wellness segment.
Gross profit stood at $7.5 million, delivering a 25.7% margin. This stability stemmed from a decrease in total cost of sales, primarily due to the closure of the Treat business and three underperforming XpresSpa locations. Cost of sales encompasses rent and occupancy costs tied to sales percentages, location-level labor—the largest component—and inventory procurement expenses. These closures directly reduced variable costs aligned with the revenue drop, preventing deeper margin erosion and highlighting management's focus on operational efficiency.
Operating income reflected a -$15.7 million loss at -53.6% margin, as elevated expenses overwhelmed gross profit gains. The company has significantly reduced operating and overhead expenses while prioritizing a return to profitability, yet segment-specific pressures and necessary restructuring costs widened losses. Net income was -$17.0 million, or diluted EPS of -$5.08, capturing the full-year toll of these dynamics.
Cash flow from operations consumed -$8.7 million, leading to free cash flow of -$11.7 million after $3.0 million in capital expenditures. This burn underscores liquidity strains from ongoing losses, though management notes post-year-end Series H financing as a critical development. The expected net proceeds are anticipated to eliminate the working capital deficit and provide sufficient liquidity for at least the next twelve months, based on the current operating plan evaluated through the issuance date. However, execution carries uncertainty as plans are not fully within company control. These measures position XWELL to stabilize amid transition, focusing on cost discipline and segment realignment for future recovery.